<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00700518</url>
  </required_header>
  <id_info>
    <org_study_id>P150-005</org_study_id>
    <nct_id>NCT00700518</nct_id>
  </id_info>
  <brief_title>Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon</brief_title>
  <official_title>A Phase I Trial of the Pharmacodynamic Dose Response to Topical Trinitrate in Patients With Raynaud's Phenomenon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Procris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Procris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the blood flow response to topical Glyceryl
      Trinitrate when applied to the skin of patient's fingers with Raynaud's Phenomenon.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigate vascular responses to topical Glyceryl Trinitrate versus placebo in patients with Raynaud's using laser Doppler imaging to measure blood flow</measure>
    <time_frame>6 visits no less than 10 hours between visits</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the dose proportionality of the microvascular response to topical Glyceryl Trinitrate</measure>
    <time_frame>6 visits no less than 10 hours between visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the systemic versus topical effect of Glyceryl Trinitrate on vascular response.</measure>
    <time_frame>6 visits no less than 10 hours between visits</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Raynaud's Phenomenon</condition>
  <arm_group>
    <arm_group_label>1.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo cream applied to 2 adjacent fingers on non-dominant hand one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.6mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.2mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers on non-dominant hand one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo cream</intervention_name>
    <description>placebo cream applied to 2 adjacent fingers of non-dominant hand one time</description>
    <arm_group_label>1.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glyceryl Trinitrate</intervention_name>
    <description>0.6mg of Glyceryl Trinitrate applied to 2 adjacent fingers on non-dominant hand one time</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glyceryl Trinitrate</intervention_name>
    <description>1.2mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glyceryl Trinitrate</intervention_name>
    <description>1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glyceryl Trinitrate</intervention_name>
    <description>2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female volunteers aged between 18 and 50 inclusive

          -  Subject has idiopathic RP (patient may have undifferentiated connective tissue disease
             with positive ANA) diagnosed for more than two (2) years

          -  If a female, subject must be non-pregnant and non-lactating

          -  The subject has provided written informed consent prior to admission to this study

        Exclusion Criteria:

          -  History of clinically relevant medical illnesses (not considering RP) that in the
             Investigator's opinion may jeopardize subject's safety or interfere with participation
             in the study, including but not limited to hemoglobinopathy, hemophilia, clinically
             significant retinal abnormalities, unstable hypertension, liver diseases, chronic
             pulmonary diseases, significant cardiovascular diseases, diabetes, thyroid diseases,
             gout, psychiatric or psychological disorders, CNS trauma or active seizure disorders,
             allergic or immunologically mediated disorders

          -  History in the past five (5) years of drug or alcohol abuse

          -  History in the past five (5) years of vascular migraine or other chronic severe
             headache

          -  History in the past five (5) years of autonomic neuropathy or postural hypotension

          -  Unwilling or unable to comply with the restrictions outlined in the protocol

          -  Current use of smoking cessation treatment, including nicotine patches

          -  History of drug allergies, anaphylaxis or laryngeal oedema, including allergy to GTN,
             propylene/ethylene glycol or common moisturizing creams

          -  Use of any nitrate medication or any phosphodiesterase inhibitor within three (3) days
             prior to or intended use one (1) day following each dosing with study drug

          -  Currently treated for hypertension

          -  Currently receiving treatment for prevention and/or treatment of RP

          -  Use of any investigational medication within 30 days prior to dosing with study
             medication or scheduled to receive an investigational drug other than during the
             course of this study

          -  Open skin lesions or pathological condition (including, but not limited to, infection)
             in the area where the study medication is to be applied

          -  Use of topical corticosteroid to the hand or fingers within 10 days of treatment with
             study drug

          -  Withdrawal of consent at any time during the study

          -  Any condition, which compromises ability to give informed consent or to communicate
             with the investigator as required for the completion of this study

          -  Previously enrolled in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Iowa-Institute for Clinical and Translational Science</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2008</study_first_posted>
  <last_update_submitted>December 29, 2008</last_update_submitted>
  <last_update_submitted_qc>December 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Matthew A. Gonda, Ph.D</name_title>
    <organization>Procris Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Raynaud's Syndrome</keyword>
  <keyword>Raynaud's Disease</keyword>
  <keyword>RP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raynaud Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

